- Home
- INM vs SNN Comparison
INM vs SNN Comparison
Compare INM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SNN
- Stock Information
- Founded
- INM 1981
- SNN 1856
- Country
- INM Canada
- SNN United Kingdom
- Employees
- INM N/A
- SNN N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- INM Health Care
- SNN Health Care
- Exchange
- INM Nasdaq
- SNN Nasdaq
- Market Cap
- INM 5.0M
- SNN 13.2B
- IPO Year
- INM N/A
- SNN 1999
- Fundamental
- Price
- INM $2.14
- SNN $36.44
- Analyst Decision
- INM
- SNN Hold
- Analyst Count
- INM 0
- SNN 4
- Target Price
- INM N/A
- SNN $33.50
- AVG Volume (30 Days)
- INM 120.8K
- SNN 682.0K
- Earning Date
- INM 11-13-2025
- SNN 10-30-2025
- Dividend Yield
- INM N/A
- SNN 2.01%
- EPS Growth
- INM N/A
- SNN 59.91
- EPS
- INM N/A
- SNN 0.56
- Revenue
- INM $4,942,633.00
- SNN $5,944,000,000.00
- Revenue This Year
- INM N/A
- SNN $7.75
- Revenue Next Year
- INM N/A
- SNN $5.40
- P/E Ratio
- INM N/A
- SNN $31.14
- Revenue Growth
- INM 7.50
- SNN 5.35
- 52 Week Low
- INM $1.72
- SNN $23.69
- 52 Week High
- INM $8.27
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- INM 45.52
- SNN 55.85
- Support Level
- INM $2.04
- SNN $34.69
- Resistance Level
- INM $2.26
- SNN $36.06
- Average True Range (ATR)
- INM 0.13
- SNN 0.41
- MACD
- INM -0.01
- SNN 0.09
- Stochastic Oscillator
- INM 21.74
- SNN 94.33
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.